

Meningitis (bacterial) and meningococcal disease: recognition, diagnosis & management

Committee Meeting 28 Post-cons

Date: Monday 6th November 2023 & Thursday 9th November 2023

Location Via Zoom

Minutes: Final

Committee members present:	
Mark Thomas (Chair)	Present for items 1 - 8
David Turner	Present for items 1 - 7
Ashifa Trivedi	Present for items 1 – 8 (Day 1: out 14:40-15:45)
Imran Jawaid	Present for items 1 – 3 and 5 - 7
Michael Griffiths	Present for items 1 - 8
Saul Faust	Present for items 1 - 4
Robert Heyderman	Present for items 1- 4 and 7- 8
Nathan Griffiths	Present for items 1 - 4
Andrew Hitchings	Present for items 5 - 8
Linda Glennie	Present for items 1 - 8
Paul Heath	Present for items 1 - 4
Richard Tubman	Present for items 5- 8
Ian Maconochie	Present for items 5 -8

In attendance:		
Angela Bennett	NICE Director of Guidelines	Present for items 1 - 8
Josh South	NICE Senior Project Manager	Present for items 1 - 8
Carlos Sharpin	NICE Associate Director	Present for items 1 - 8
Odette Megnin-Viggars	NICE Senior Systematic Reviewer	Present for items 1 – 8
Paul Jacklin	NICE Senior Health Economist	Present for items 1 - 8
Aye Paing	NICE Systematic Reviewer	Present for items 1 - 8
Catrina Charlton	NICE Commissioning Manager	Present for items 1 - 8
James Hall	NICE Editor	Present for items 1 -8
Stephen Murphy	NICE Clinical Advisor	Present for items 1 -8
Adam Storrow	NICE Cost Impact Lead	Present for item 7

Apologies:

Lisa Boardman	NICE Guideline Lead	Both days
Melissa Bolessa	NICE Project Manager	Both days
Robert Tubman	Co-opted Member	Day 1 only
David Turner	Topic Advisor	Day 1 – PM Only
Robert Heyderman	GC Member	Day 2 AM only
Paul Heath	Co-opted Member	Day 2 only
Saul Faust	GC Member	Day 2 only

Day 1: 06th November 2023

1. Welcome and actions

The Chair welcomed the committee members and attendees to the first day of the post-consultation guideline committee meeting on Meningitis (bacterial) and meningococcal disease: recognition, diagnosis & management. The Chair thanked the committee for joining the meeting virtually.

The Chair informed the committee that apologies had been received as noted above.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting. No new interests were declared.

The Chair introduced, Carlos Sharpin, Associate Director and Angela Bennett, Director of Guidelines who outlined the aims of the meeting.

2. Morning presentations

Carlos Sharpin, Associate Director and Angela Bennett, Director of Guidelines led the committee through a review of stakeholder comments on the following sections of the guideline:

- Section 1.6: Antibiotics for bacterial meningitis in hospital:
 - o General
 - o Unknown causative organism
 - o Known causative organism.
- Section 1.7: Antibiotics for meningococcal disease in hospital
- Section 1.2: Antibiotics outside hospital

The committee discussed the stakeholder comments and agreed to make changes to the guideline where needed.

3. Afternoon presentations

Carlos Sharpin, Associate Director, Angela Bennett, Director of Guidelines and James Hall, NICE Editor led the committee through a review of stakeholder comments on the following sections of the guideline:

- Section 1.1: Recognising bacterial meningitis and meningococcal disease
 - o General
 - o Bacterial meningitis
 - o Meningococcal disease

The committee discussed the stakeholder comments and agreed to make changes to the recommendations where needed.

4. Any other business

The Chair closed the meeting at 17:00

Day 2: 09th November 2023

5. Welcome and actions

The Chair welcomed the committee members and attendees to the second day of the post-consultation guideline committee meeting on Meningitis (bacterial) and meningococcal disease: recognition, diagnosis & management. The Chair thanked the committee for joining the meeting virtually.

The Chair informed the committee that apologies had been received as noted above.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting. No new interests were declared.

The Chair introduced, Carlos Sharpin, Associate Director and Angela Bennett, Director of Guidelines who outlined the aims of the meeting.

6. Morning presentations

Carlos Sharpin, Associate Director and Angela Bennett, Director of Guidelines led the committee through a review of stakeholder comments on the following sections of the guideline:

- Section 1.4: Investigations for bacterial meningitis
- Section 1.5: Investigations for meningococcal disease
- Section 1.8
- Section 1.10: management after bacterial meningitis/ meningococcal disease
- Section 1.11: info and support after diagnosis
- Section 1.12:
- Section 1.13: Care after hospital discharge

The committee discussed the stakeholder comments and agreed to make changes to the guideline where needed.

7. Afternoon presentations

The Chair introduced Adam Storrow, Cost Impact Lead who led the committee through stakeholder comments and the potential resource impact of recommendations.

Carlos Sharpin, Associate Director and Angela Bennett, Director of Guidelines led the committee through a review of stakeholder comments on the following sections of the guideline:

- Section 1.9: Corticosteroids

The committee discussed the stakeholder comments and agreed to make changes to the guideline where needed.

The committee discussed why no research recommendations had been made in certain areas.

The committee also discussed miscellaneous stakeholder comments and those received regarding terms used in the guideline.

Carlos Sharpin, Associate Director and Angela Bennett, Director of Guidelines gave the committee a summary of the next steps following the post-consultation meeting.

8. Any other business

The Chair closed the meeting at 16:30